Certificate of Analysis
Third Party Tested
Molecular Profile
Compound
PT-141
Batch #
20260605
Formula
C50H68N14O10
Mol Wt
1025.182 g/mol
CAS
189691-06-3
Latest
ISO 17025
8× Testing
99.82 %
Purity
VariantPT-141
COA ##13797
Labeled10mg
Validation KeyAXISBIOTECH
Tested08/25/26
Full QC Panel - 8× tested
✓
Purity (HPLC) - 99.82%
✓
Net Peptide Content - 10mg
✓
Identity (HPLC) - PT-141
✓
Fentanyl Screen - Not Detected
✓
HPLC Conformity mean - >99%
✓
ISO/IEC 17025 Accredited
Storage Requirements
Stability Information
Lyophilized (powder)
−20°C long-term
2–8°C
Reconstituted
Recommended condition
Light protection
Store away from light
Sealed lyophilized vials are heat-stable; refrigerating or freezing sealed vials is optional. 2–8°C applies to reconstituted solutions.
Peer-Reviewed Literature
Research & References
Research and reference material related to this compound.
01
VYLEESI (bremelanotide) — FDA Approval for Hypoactive Sexual Desire Disorder
02
Bremelanotide for hypoactive sexual desire disorder: FDA approval and pharmacology
03
Randomized, double-blind, placebo-controlled trial of bremelanotide for female sexual dysfunctions
04
Melanocortin receptors mediate alpha-MSH-induced penile erection and yawning
05
Melanotan II, a cyclic melanotropic peptide, induces penile erection via brain and spinal cord melanocortin receptors
Safety & Regulatory Compliance Warning
These products are intended solely for laboratory research and analytical applications. They have not been evaluated by the U.S. Food and Drug Administration (FDA) and are not approved for therapeutic use, diagnosis, treatment, or prevention of disease. Under no circumstances should these materials be used for human or animal consumption.
